| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/21/2004 | WO2004042079A1 Induction of the mitochondrial permeability transition |
| 05/21/2004 | WO2004042021A2 Method for inhibiting calcium-induced cell death |
| 05/21/2004 | WO2004042020A2 Methods for treatment of thiol-containing compound deficient conditions |
| 05/21/2004 | WO2004042002A2 Compounds for modulating rna interference |
| 05/21/2004 | WO2004041924A2 Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| 05/21/2004 | WO2004041823A1 Novel amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| 05/21/2004 | WO2004041819A1 Pyrazolonaphthyridine derivative |
| 05/21/2004 | WO2004041817A1 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof |
| 05/21/2004 | WO2004041809A2 Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands |
| 05/21/2004 | WO2004041802A1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 05/21/2004 | WO2004041800A1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 05/21/2004 | WO2004041789A1 Compositions useful as inhibitors of jak and other protein kinases |
| 05/21/2004 | WO2004041782A1 Indoles useful in the treatment of androgen-receptor related diseases |
| 05/21/2004 | WO2004041777A2 Heteroarylpiperidine modulators of chemokine receptor activity |
| 05/21/2004 | WO2004041758A1 New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonistics |
| 05/21/2004 | WO2004041755A2 Quinazolinone compounds as calcilytics |
| 05/21/2004 | WO2004041324A2 Transdermal delivery of fentanyl |
| 05/21/2004 | WO2004041309A1 Drugs comprising combination of elastase inhibitor with blood coagulation system and/or fibrinolysis system enzyme inhibitor |
| 05/21/2004 | WO2004041301A1 Antidiuretics |
| 05/21/2004 | WO2004041297A2 Modified cytokines for use in cancer therapy |
| 05/21/2004 | WO2004041295A1 New alpha-glucosidase inhibitors from a natural source |
| 05/21/2004 | WO2004041293A1 Aqueous activated components conveyed in a non-aqueous carrier system |
| 05/21/2004 | WO2004041292A2 C-type lectin binding molecules, identification and uses thereof |
| 05/21/2004 | WO2004041291A1 High affinity receptors for helicobacter pylori and use thereof |
| 05/21/2004 | WO2004041290A1 Use of fosinopril to reduce cardiovascular events in dialysis patients |
| 05/21/2004 | WO2004041289A1 Cardiovascular protection using anti-aldosteronic progestins |
| 05/21/2004 | WO2004041288A1 Hormone replacement therapy with drospirenone |
| 05/21/2004 | WO2004041287A1 Delivery composition and method |
| 05/21/2004 | WO2004041286A1 Benzodiazepine derivatives for the treatment of diabetes mellitus |
| 05/21/2004 | WO2004041284A1 Inclusion complex of anti-tubercular rifampicin with beta-cyclodextrin or 2-hydroxypropyl beta-cyclodextrin and a process for producing the same |
| 05/21/2004 | WO2004041283A1 Device and method for treating combination dependencies |
| 05/21/2004 | WO2004041282A1 Receptor regulator |
| 05/21/2004 | WO2004041281A1 Treatment of hyperkinetic movement disorder with donepezil |
| 05/21/2004 | WO2004041280A1 Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor |
| 05/21/2004 | WO2004041279A1 Gamma-aminoamide modulators of chemokine receptor activity |
| 05/21/2004 | WO2004041278A1 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma |
| 05/21/2004 | WO2004041276A1 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| 05/21/2004 | WO2004041275A1 Substituted 4-alkoxyoxazol derivatives as ppar agonists |
| 05/21/2004 | WO2004041274A1 Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
| 05/21/2004 | WO2004041273A1 DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS |
| 05/21/2004 | WO2004041272A2 Use of serotonin receptor antagonists for the treatment of sleep apnea |
| 05/21/2004 | WO2004041271A1 Oromucosal formulation and process for preparing the same |
| 05/21/2004 | WO2004041270A1 Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one |
| 05/21/2004 | WO2004041269A2 New use for pharmaceutical composition |
| 05/21/2004 | WO2004041268A1 Combination comprising docetaxel and a cdk inhibitor |
| 05/21/2004 | WO2004041267A1 Combination comprising a cdk inhibitor and cisplatin |
| 05/21/2004 | WO2004041266A1 Receptor function controlling agent |
| 05/21/2004 | WO2004041265A1 Blood fluidity improving agent |
| 05/21/2004 | WO2004041264A1 2-oxo-ethanesulfonamide derivates |
| 05/21/2004 | WO2004041263A1 New pharmaceutical compositions containing ambroxol and isopropamide iodide |
| 05/21/2004 | WO2004041262A1 Combination of a cdk inhibitor and mitoxantrone |
| 05/21/2004 | WO2004041261A1 A kind of camphor spray and its preparation and a product containing it |
| 05/21/2004 | WO2004041260A1 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections |
| 05/21/2004 | WO2004041259A1 Treatment of female sexual dysfunction |
| 05/21/2004 | WO2004041258A2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 05/21/2004 | WO2004041257A2 Novel nutraceutical compositions comprising epigallocatechin gallate |
| 05/21/2004 | WO2004041256A2 Safe chemical uncouplers for the treatment of obesity |
| 05/21/2004 | WO2004041253A1 Wet granulation process |
| 05/21/2004 | WO2004041252A1 Controlled release carvedilol compositions |
| 05/21/2004 | WO2004041250A2 Nanoparticulate fibrate formulations |
| 05/21/2004 | WO2004041249A1 Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same |
| 05/21/2004 | WO2004041246A1 Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs |
| 05/21/2004 | WO2004041245A2 Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases |
| 05/21/2004 | WO2004041243A2 Stable amorphous celecoxib composite and process therefor |
| 05/21/2004 | WO2004041240A1 Controlled and continued delivery of rifaximin and/or other substances |
| 05/21/2004 | WO2004041236A1 Composition for preparation for external use on skin and method of using the same |
| 05/21/2004 | WO2004041235A1 Novel dermatological and/or cosmetologic hydrating and anti-irritation compositions |
| 05/21/2004 | WO2004041234A1 Topical anhydrous delivery system for antioxidants |
| 05/21/2004 | WO2004041217A2 Synthetic lactone formulations and method of use |
| 05/21/2004 | WO2004041215A2 Methods for treating gastroesophageal reflux disease |
| 05/21/2004 | WO2004041214A2 Methods for treating migraine |
| 05/21/2004 | WO2004041211A2 INHIBITORS OF β-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER’S DISEASE OR MILD COGNITIVE IMPAIRMENT |
| 05/21/2004 | WO2004041210A2 Antibacterial agents |
| 05/21/2004 | WO2004041209A2 Transcription factor modulating compounds and methods of use thereof |
| 05/21/2004 | WO2004041208A2 Controlled absorption of mixed thyroyd hormone formulations |
| 05/21/2004 | WO2004041207A2 Ghb treatment methods |
| 05/21/2004 | WO2004041205A2 Ha4, a new osteoblast- and chondrocyte-specific small secreted peptide, compositions and methods of use |
| 05/21/2004 | WO2004041201A2 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| 05/21/2004 | WO2004041199A2 N-acetyl-d-glucosamine (nag) supplemented food products and beverages |
| 05/21/2004 | WO2004041198A2 Heat pasteurized liquids containing glucosamine |
| 05/21/2004 | WO2004041197A2 Methods of inhibiting glial scar formation |
| 05/21/2004 | WO2004041195A2 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 05/21/2004 | WO2004041193A2 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5 |
| 05/21/2004 | WO2004041191A2 Methods for the treatment, prevention and management of macular degeneration |
| 05/21/2004 | WO2004041190A2 Composition for the treatment of macular degenration |
| 05/21/2004 | WO2004041189A2 A method for inhibiting cancer development by fatty acid synthase inhibitors |
| 05/21/2004 | WO2004041188A2 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | WO2004041187A2 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | WO2004041185A2 Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| 05/21/2004 | WO2004041181A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
| 05/21/2004 | WO2004041178A2 A protectant for uv-induced skin damage |
| 05/21/2004 | WO2004041176A2 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus |
| 05/21/2004 | WO2004041174A2 Compositions for darkening the skin and/or hair |
| 05/21/2004 | WO2004041171A2 Shivering supression during cooling to lower body temperature |
| 05/21/2004 | WO2004041169A2 Modulation of cell fates and activities by phthalazine diones |
| 05/21/2004 | WO2004041165A2 Compounds for the treatment of metabolic disorders |
| 05/21/2004 | WO2004041164A2 Kinase inhibitors |
| 05/21/2004 | WO2004041162A2 Inhibitors of akt activity |
| 05/21/2004 | WO2004041161A2 Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity |
| 05/21/2004 | WO2004041158A2 Rifalazil compositions and therapeutic regimens |